On October 11, 2012, Somaxon effected a 1-for-8 reverse stock split of its common stock and a decrease in the number of authorized shares of its common stock from 100,000,000 to 25,000,000 shares. The reverse stock split and the …
SAN DIEGO & MONTREAL--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) and Paladin Labs Inc. (TSX ... and Paladin will purchase 2,184,769 shares of Somaxon’s common stock for a purchase price of US$5 million. …
Somaxon Pharmaceuticals Inc. (SOMX) Monday said the FDA has determined that the new drug application for Silenor, …
p><p><b>About <org value="NASDAQ-NMS:SOMX" idsrc="xmltag.org">Somaxon Pharmaceuticals ... and the impact …
Somaxon Pharmaceuticals Inc. (SOMX) soared last week after the FDA approved its Silenor ... Before the FDA approval, this was a $4.00 stock. It ran to $10.60 before closing at $8.25 last week as major profit taking came into play. Last …
Translation: The upward trend remains intact but there's some disquieting underlying technical deterioration that we must take note ... the economy up to full and steady growth. As for why the stock market is rallying on this lukewarm …
THE WOODLANDS, Texas--(BUSINESS WIRE)--Pernix Therapeutics Holdings, Inc. (“Pernix”) (NASDAQ: PTX) today announced the completion of its acquisition of Somaxon Pharmaceuticals, Inc. (“Somaxon”) (NASDAQ: SOMX ...
The firm retreated its price target of $15. Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) is under deep selling …
Somaxon Pharmaceuticals (SOMX-NASDAQ) has announced essentially failed results from the company’s Phase 2/3 clinical trial evaluating 20 mg and 40 mg of oral nalmefene hydrochloride, an opiate antagonist, in patients with a …
Crew Group, Inc. (NYSE: JCG), Netezza Corporation (NYSE: NZ), 3PAR, Inc. (NYSE: PAR), Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), SunPower Corporation (NASDAQ: SPWRA) and Sterling Financial Corp. (NASDAQ: STSA). …